Longevity Hype in Silicon Valley: Will Traditional Approach to BioTech Investment Lead to a Longevity Boom, Bubble or Bust?
Earlier this year, Deep Knowledge Group’s Longevity-focused analytical subsidiary Aging Analytics Agency released an 1100+ page analytical report titled “Longevity Industry in California: Landscape Overview 2019”. The report provided a comprehensive overview of the history, present state and near-future trajectory of the Longevity Industry in California, profiling leading companies, investors, influencers, research labs, non-profit and governmental organizations active in the region's Longevity sphere.
The Swiss Longevity Valley: How Switzerland Will Become a Global Longevity Financial MegaHub by 2025
As a Switzerland-based Financial Industry Professional, the nation’s unique strengths in the financial sector, and the international policy sector, have been clear to me for a long time. But it was not until I met Dmitry Kaminskiy, Co-Founder of Deep Knowledge Group, that Switzerland’s equally-unique strengths and prospects in the Longevity Industry - and its potentials to reap extremely promising synergies between these two domains - became apparent to me. I am excited to promote this agenda and to help steer the direction of ongoing Swiss-based Longevity activities towards a future that can enable the nation to become a world-class Longevity MegaHub.
位于香港的投资公司Deep Knowledge Ventures在2014年因为在董事会引入计算机算法而声名大振。该公司旗下管理的资产约为1亿欧元，希望找到一种方法来实施数据驱动型的投资策略，而不是依靠人类的直觉以及与创始人之间的关系。执行合伙人德米特里·卡明斯基（Dmitry Kaminskiy）表示，该算法大多用来行使否决权，如果它发现危险信号，Deep Knowledge就不会投资。
自从Deep Knowledge的人工智能技术参与董事会五年来，市场上并没有出现多少真正意义上的效仿者。事实上，Deep Knowledge自身也已经转移其精力，而且不再使用这一算法。美国西北大学（Northwestern University）凯洛格管理学院（Kellogg School of Management）的教授布莱恩·乌兹（Brian Uzzi）说：“如今，重大策略决策基于直觉”—也就是说，由人来制定—“因为我们缺乏相关数据。”实际上，各大公司所做重大决策的数量还不足以用来有效地培训算法。
Landmark Longevity Summits at King's College London Demonstrate That Top Financial and Tech Corporations Are Committed to Longevity
This week two Landmark International Longevity Summits in London attracted the attention of scientists, government officials, major financial corporations, insurance companies, investment banks, and technology companies from around the world. The Landmark AI for Longevity Summit and the First International Longevity Policy and Governance Summit at King's College London are expected to become the world-leading forums for the Longevity Industry.
Landmark Summits Reveal How the Future of National Economies Will Be Reshaped by the Intersection of AI, Longevity, Finance and Governance
November 14, 2019, London, UK: Deep Knowledge Group executives Dmitry Kaminksiy and Eric Kihlstrom spoke at a landmark one-day event held yesterday at King’s College London with the strategic support Deep Knowledge Group. The event united two Longevity-themed summits under the shared strategic agenda of enabling a paradigm shift from treatment to prevention and from prevention to Precision Health via the synergistic efforts of science, industry, AI, policy and governance, to enable the UK to become an international leader in Healthy Longevity.
Deep Knowledge Group Announces Strategic Support of Landmark AI for Longevity Summit at King’s College London
October 25, 2019, London, UK: Deep Knowledge Group announces its strategic support of a conference on the topic of Longevity for the first time since the Big Data Science in Medicine Conference at Oxford University in 2014, and will be unveiling the cumulative knowledge it has aggregated, systematized and refined over the past 5 years on the nexus of Artificial Intelligence, Longevity, Health and Wealth to a select group of attendees.
Switzerland: Hub of a new ‘Longevity Valley’?
Aging Analytics Agency special case study reveals how Switzerland could become the new European Longevity hotspot.
According to our friends the Aging Analytics Agency, Switzerland may be the next leader in Longevity and an important part of creating a fourth industrial revolution. A revolution in human Longevity will transform the growing aging population from a possible ‘silver tsunami’ threat into an opportunity.
Deep Knowledge Ventures Flagship Portfolio Company
Insilico Medicine Closes Major $37 Million Series B Round
Insilico Medicine has successfully closed its $37 million Series B funding round led by Qiming Venture Partners and joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, Bold Capital Partners, Longevity Vision Fund, Juvenescence, and Michel Antonov
Pharma’s AlphaGo Moment: For the First Time Artificial Intelligence Has Designed a New Drug in 21 Days
For the First Time, Artificial Intelligence Has Designed and Validated a New Drug in Days
Artificial intelligence gets a seat in the boardroom
Hong Kong venture capitalist sees AI running Asian companies within 5 years
ESG Frontiers: Artificial intelligence: The rise of the responsible robots
Far from the evil cyborgs of science fiction, AI is emerging as a sustainable investment theme
Aging Analytics Agency Releases Global Overview of Government-Led Longevity Development Initiatives
Aging Analytics Agency has published a new, 315-page open-access report “National Longevity Development Plans: Global Overview 2019 (First Edition)”, which delivers a comprehensive international overview of the projects, initiatives, and efforts that different countries are making in order to combat the issues associated with Ageing Population.
MIT School of Engineering first quarter 2019 awards
Every quarter, the School of Engineering publicly recognizes their achievements by highlighting the honors, prizes, and medals won by faculty working in our academic departments, labs, and centers.
Regina Barzilay, Manolis Kellis, Tommi Jaakola and Peter Szolovits were named among “Top 100 AI Leaders in Drug Discovery and Advanced Healthcare” by Deep Knowledge Analytics on Feb. 1.
MIT acknowledged AI ranking made by Deep Knowledge Analytics.
This week four CSAIL faculty were named among the top 100 global leaders in artificial intelligence for health, according to a new report developed by a top technology think-tank.
Deep Knowledge Analytics’s “Top 100 AI Leaders in Drug Discovery and Advanced Healthcare”.
The 100 Leading Pioneers
Of AI Drug Development
Deep Knowledge Analytics picked the 'Top 100 AI Leaders in Drug Discovery and Advanced Healthcare’ out of an initial pool of 500 outstanding candidates. Unless a new AI winter wind blows and sweeps over the science explorers, their work is quite likely to enhance the quality of life surpassing the most vivid science fiction imagination.
An Insight Of AI's Penetration In Drug Development Market
A recent article about AI-based drug development, indicates the progressive use of A.I. technologies for the drug production industry, mining the huge amount of data collected from the pharmaceutical companies’ data centers. Thanks to Deep Knowledge Ventures which a couple of days ago updated their research data, we took the opportunity to delve into the latest developments of this market.
Presentation in the House of Lords
Dmitry Kaminskiy Presents Landmark “AI in UK Industry Report” in the House of Lords of UK Parliament alongside Lord Clement-Jones and Birgitte Andersen.
The lucrative business
of living longer
Our report "Longevity Industry in UK. Landscape Overviiew 2018" was mentioned by Financial Times in a huge article about Longevity
I have worked with the Deep Knowledge Group and its various subsidiary and partner organizations in a number of capacities over the past three years. Before serving as Deputy Director of Aging Analytics Agency, I served as Deputy Director of the Biogerontology Research Foundation, and a member of its Board of Trustees, from 2017 - 2018. One of the projects I am most proud of during my tenure there was spearheading the Biogerontology Research Foundation’s part of a multi-institution project to classify aging as a disease during the World Health Organization’s most recent round of revisions to their International Classification of Disease (ICD-11) - a health care classification system that providing a framework of diagnostic codes for classifying diseases, which serves as the example followed by the majority of developed nations' drug regulatory agencies for determining which conditions are officially classified as diseases and, therefore, which conditions can be targeted by therapeutic interventions, tested, and ultimately approved.